Moderna, Inc. (MRNA) News
Track canonical SquawkNews coverage tagged to MRNA, Moderna, Inc.. This hub brings together deduplicated headlines about united states, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 108 indexed stories across 31 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Moderna jumps on personalized mRNA Phase 3 success; raises $2.96B via 0% notes
Moderna surged on Phase 3 success for a personalized mRNA cancer vaccine with Keytruda in resected stage IIB–IV melanoma. The company also raised about $2.96B through 0% convertible notes due 2032 with capped calls.
EQUITY | Sep 07, 2026, 11:22 AM UTC
L
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels - Heard on the Street — WSJ
By David WainerThe excitement surrounding Moderna and Merck's personalized mRNA cancer vaccine added more than $50 billion in combined market value for the two drug companies. But it is also creating a gold rush in a gro
COMMODITIES | Sep 04, 2026, 09:30 AM UTC
M
Moderna shares fall after Rothschild & Co Redburn downgrade to Sell
Moderna shares fell 2.9% in the afternoon session after Rothschild & Co Redburn analyst Simon Baker downgraded the company to Sell from Neutral on valuation concerns.
EQUITY | Sep 03, 2026, 07:45 PM UTC
L
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense — Barrons.com
By Paul R. La MonicaWant a prescription for investing success? Check out Big Pharma companies, biotechs, and other healthcare stocks.The healthcare sector has been on a hot streak, trouncing the broader market, and there
EQUITY | Sep 03, 2026, 05:40 PM UTC
L
Rothschild cuts Moderna to Sell from Neutral, analyst note
Rothschild & Co analyst Simon Baker cut Moderna from Neutral to Sell in a research note Thursday, marking the company’s second Sell rating. The downgrade was described as having little link to commercial potential or pip
EQUITY | Sep 03, 2026, 03:10 PM UTC
M
Moderna cut to sell from neutral by Rothschild & Co
Rothschild & Co downgraded Moderna to sell from neutral and raised its price target to $81.00 a share from $40.00.
EQUITY | Sep 03, 2026, 12:01 PM UTC
L
Moderna shares slip Wednesday amid yield pressures and recent financing
Moderna (MRNA) is lower Wednesday morning, down 3.07% to $149.54 at publication. The move comes after a trailing-month 170% surge alongside a recently closed $2.6 billion convertible notes deal as benchmark yields remain
RATES | Sep 02, 2026, 02:42 PM UTC
M
Moderna completes $3.0B convertible notes offering due 2032
Moderna completed a $3.0 billion private offering of 0.00% Convertible Senior Notes due March 1, 2032 and executed the related indenture. Notes are convertible at $210.58 per share, with settlement in cash, stock, or com
EQUITY | Sep 01, 2026, 08:44 PM UTC
L
Moderna announces investor-conference participation in September 2026
Moderna said it will participate in upcoming investor conferences in September 2026. A live webcast of the presentations will be available under “Events and Presentations” in the Investors section.
EQUITY | Sep 01, 2026, 11:00 AM UTC
L
MRNA - Moderna to Present at Upcoming Conferences in September 2026
MRNA - Moderna to Present at Upcoming Conferences in September 2026
EQUITY | Sep 01, 2026, 11:00 AM UTC
L
Moderna leads S&P 500 in August; Edison International sinks
Moderna led the S&P 500 in August while Edison International sank, according to Barrons.com.
EQUITY | Aug 31, 2026, 04:51 PM UTC
L
22 best-performing stocks of August, as the software industry continues its recovery
22 best-performing stocks of August, as the software industry continues its recovery
EQUITY | Aug 31, 2026, 04:22 PM UTC
M
FDA approves seasonal Covid-19 vaccines from Moderna, Pfizer, BioNTech, Novavax
FDA approved seasonal Covid-19 vaccines from Moderna, Pfizer, BioNTech and Novavax, according to an update.
REGULATION | Aug 28, 2026, 03:26 PM UTC
L
Argus sets Moderna price target at $180.00 per share
Argus Research announced a $180.00 per-share price target for Moderna.
EQUITY | Aug 28, 2026, 12:00 PM UTC
L
Moderna prices upsized $2.6B convertible notes offering
MRNA priced an upsized $2.6 billion offering of convertible senior notes.
EQUITY | Aug 28, 2026, 11:11 AM UTC
L
Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
EQUITY | Aug 28, 2026, 10:00 AM UTC
L
Moderna boosters approved; Intismeran PFS; $2B notes
Moderna (MRNA) boosters have been approved. Intismeran PFS and $2B notes are also in the update.
EQUITY | Aug 28, 2026, 07:14 AM UTC
M
US FDA approves updated COVID vaccines for 2026-27 season
US FDA approves updated COVID vaccines for the 2026-27 season.
REGULATION | Aug 27, 2026, 09:41 PM UTC
M
FDA approves seasonal Covid-19 vaccines from Moderna, Pfizer, BioNTech
FDA approved seasonal Covid-19 vaccines from Moderna, Pfizer and BioNTech.
REGULATION | Aug 27, 2026, 09:04 PM UTC
M
Moderna receives FDA approval for updated 2026-2027 COVID-19 vaccines
Moderna (MRNA) said the U.S. FDA approved its updated 2026-2027 COVID-19 vaccines.
REGULATION | Aug 27, 2026, 07:58 PM UTC
L
Moderna’s $2B Convertible-Note Deal To Focus On Oncology Growth, Debt Repayment — But Retail Calls It A ‘Bull Trap’
Moderna’s $2B Convertible-Note Deal To Focus On Oncology Growth, Debt Repayment — But Retail Calls It A ‘Bull Trap’
EQUITY | Aug 27, 2026, 01:26 PM UTC
M
Nasdaq poised to lead Wall St after Nvidia puts AI fears to rest
Nasdaq poised to lead Wall St after Nvidia puts AI fears to rest
EQUITY | Aug 27, 2026, 12:58 PM UTC
L
Moderna to sell $2 billion convertible notes in private placement
Moderna plans to sell $2 billion convertible notes in a private placement.
EQUITY | Aug 27, 2026, 11:44 AM UTC
M
Moderna proposes $2.0B convertible senior notes private placement
Moderna announced a proposed private placement of $2.0 billion of convertible senior notes.
EQUITY | Aug 27, 2026, 11:21 AM UTC
L
S&P 500, Nasdaq finish down but near flat ahead of Nvidia
S&P 500, Nasdaq finish down but near flat ahead of Nvidia
RATES | Aug 26, 2026, 08:26 PM UTC
H
Indexes end close to flat after hot inflation data ahead of Nvidia earnings
Indexes end close to flat after hot inflation data ahead of Nvidia earnings
MACRO | Aug 26, 2026, 08:01 PM UTC
H
Wall Street dips on hot inflation data ahead of Nvidia earnings
Wall Street dips on hot inflation data ahead of Nvidia earnings
MACRO | Aug 26, 2026, 06:23 PM UTC
H
Wall St awaits Nvidia's AI verdict after hot inflation data
Wall St awaits Nvidia's AI verdict after hot inflation data
MACRO | Aug 26, 2026, 04:25 PM UTC
H
Moderna shares slip in premarket after 150% surge
Moderna (MRNA) is trading slightly lower Wednesday morning, with shares down 2.75% to $154.47 in premarket trading after a prior move of more than 150%.
EARNINGS | Aug 26, 2026, 01:26 PM UTC
H
Moderna, Cadeler, Marvell among stocks rising on Tuesday
Moderna, Cadeler and Marvell Technology trade higher Tuesday alongside other names after analyst upgrades, a higher FY26 sales guide and other company-specific developments.
EARNINGS | Aug 25, 2026, 02:03 PM UTC
L
Moderna upgraded by Wolfe Research to Peerperform
Wolfe Research upgrades Moderna (MRNA) to Peerperform from Underperform, according to TradeXchange Newsdesk.
EQUITY | Aug 25, 2026, 11:50 AM UTC
M
Analyst upgrades and ratings changes hit AMD, MRNA, and peers
TradeXchange Newsdesk reports top broker rating actions: AMD lifted to STRONG BUY (RJ BFH) and OUTPERFORM (Wolfe), while MRNA is set to PEER PERFORM (Wolfe) and other peers are kept at or moved to neutral/overweight.
EQUITY | Aug 25, 2026, 10:49 AM UTC
H
Moderna, Walmart and Strategy drive retail buzz after news flow
Retail traders focused on Moderna, Walmart, Strategy, Broadcom and SpaceX this week, with Moderna on positive Phase 3 cancer vaccine data, Walmart on fiscal second-quarter results, and Strategy on a stock sale and unchan
EARNINGS | Aug 21, 2026, 10:00 PM UTC
H
U.S. Treasury doubles long-bond buybacks as yields retreat
The U.S. Treasury says it will at least double its buybacks of 10- to 30-year debt after 30-year yields hit 5.27%, briefly easing long-end rates.
EARNINGS | Aug 21, 2026, 08:01 PM UTC
H
Sector ETF outperformers led by HOOD, MRNA, TSLA, and FCX
Hammerstone MarketTalk lists sector ETF outperformers, led by HOOD in Financials, MRNA in Healthcare, TSLA in Consumer Discretionary and FCX in Materials.
EQUITY | Aug 21, 2026, 07:47 PM UTC
H
Iovance Biotherapeutics trades at 52-week high after sector-linked momentum
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) is trading at a 52-week high despite no company-specific news, while the post also cites second-quarter results and reaffirmed fiscal 2026 sales guidance.
EARNINGS | Aug 20, 2026, 05:14 PM UTC
H
Alnylam cuts 2026 Amvuttra revenue guidance
Alnylam Pharmaceuticals cuts full-year 2026 revenue guidance for its Amvuttra franchise after early demand was inflated by a rush of pent-up patients.
EARNINGS | Aug 20, 2026, 04:03 PM UTC
H
MRNA trades at session lows, down 18%
MRNA is reported trading at lows of -18%, with Hammerstone MarketTalk citing the move as the session low level.
EQUITY | Aug 20, 2026, 01:33 PM UTC
M
Merck and Moderna report interim Phase 3 vaccine data hits endpoint
Merck and Moderna said interim Phase 3 data for Moderna’s personalized cancer vaccine met its primary endpoint, with Wells noting potential beneficiaries include RGEN, DHR, TMO and MRVI.
EQUITY | Aug 20, 2026, 01:25 PM UTC
H
Premarket movers: Coty, Advance Auto, Wolfspeed drop on earnings
Top big-cap negative premarket movers include Coty -20%, Advance Auto Parts -19%, Wolfspeed -10%, and Walmart -8%, with several flagged as earnings-related.
EARNINGS | Aug 20, 2026, 01:13 PM UTC
M
Merck target raised to $160 after Moderna cancer therapy data
Goldman Sachs raises its price target on Merck to $160 from $140 after partner mRNA cancer therapy data involving Moderna.
EQUITY | Aug 20, 2026, 12:55 PM UTC
H
MRNA raises price target to $120 from $67 after Phase 3 data
MRNA’s MRK-partnered intismeran autogene plus Keytruda therapy price target is lifted to $120 from $67 following a reported positive late-stage Ph3 result in completely resected Stage IIB-IV melanoma.
EQUITY | Aug 20, 2026, 12:55 PM UTC
L
Tempus AI gains as BTIG lifts price target, cancer trial readthrough in focus
Tempus AI Inc. shares are trading higher Thursday after BTIG maintained a Buy rating and raised its price forecast to $80, while investors also focus on a Phase 3 cancer trial readthrough tied to the pending Personalis a
EQUITY | Aug 20, 2026, 12:35 PM UTC
H
Moderna jumps on vaccine cancer breakthrough; stock tops 491% for year
Moderna (MRNA) stock is now up 491% for the year after surging 177% on Wednesday following its vaccine cancer breakthrough, according to the raw item.
EQUITY | Aug 20, 2026, 11:30 AM UTC
M
MRNA paring some of yesterday’s gain, down 12% premarket
MRNA is paring some of yesterday’s gain, with the stock down 12% in premarket trading, according to Hammerstone MarketTalk; no catalyst was supplied.
EQUITY | Aug 20, 2026, 11:17 AM UTC
L
MRK MRNA raising PTs — whats priced in, whats next? @ UBS
MRK MRNA raising PTs — whats priced in, whats next? @ UBS
EQUITY | Aug 20, 2026, 11:09 AM UTC
L
BAP BILL CPB IOVA JKHY MRK MRNA MRVL NU SJM TGT TJX TOL ZM LOW MAR PT changes @ UBS
BAP BILL CPB IOVA JKHY MRK MRNA MRVL NU SJM TGT TJX TOL ZM LOW MAR PT changes @ UBS
EQUITY | Aug 20, 2026, 11:04 AM UTC
L
MRNA: Morgan Stanley keeps Equalweight, raises PT to $89
Morgan Stanley maintains an Equalweight rating on MRNA and raises its price target to $89, according to TradeXchange Newsdesk.
EQUITY | Aug 20, 2026, 10:35 AM UTC
H
U.S. stock futures fall after Trump launches Iran economic offensive
U.S. stock futures are lower as President Donald Trump announces “Operation Economic Fury” against Iran, lifting geopolitical tensions and pushing Brent crude higher.
EARNINGS | Aug 20, 2026, 09:24 AM UTC
L
Morgan Stanley raises Moderna price target to $89, keeps Equal Weight
Morgan Stanley raises its price target on Moderna to $89 from $39 and maintains an Equal Weight rating.
EQUITY | Aug 19, 2026, 11:31 PM UTC
L
BofA upgrades Moderna to Neutral, raises target to $170
BofA upgrades Moderna to Neutral from Underperform and lifts its price target to $170 from $40.
EQUITY | Aug 19, 2026, 11:30 PM UTC
L
Morgan Stanley raises Moderna target to $89, keeps Equal Weight
Morgan Stanley reiterates Equal Weight on Moderna and raises its price target to $89 from $39, according to the note.
EQUITY | Aug 19, 2026, 09:20 PM UTC
H
MRNA extends after-hours gains, adding 9% to $174.38
MRNA is extending gains after hours, rising another 9% after settling near the highs at $174.38, following a +177% move on the day.
EQUITY | Aug 19, 2026, 08:27 PM UTC
M
Moderna tracking to close at the highs, up 179% to $176.50
Moderna (MRNA) is tracking to close at the highs at $176.50, up 179% or $113, according to the market talk item.
EQUITY | Aug 19, 2026, 07:56 PM UTC
L
TEM shares now up over 23% PRME +17% RXRX +11% and DNA about 16%, extending gains all day in Precision Medicine, or Biomedical/genetics sub
TEM shares now up over 23% PRME +17% RXRX +11% and DNA about 16%, extending gains all day in Precision Medicine, or Biomedical/genetics sub-areas which have all rallied behind the MRNA/MRK news today
EQUITY | Aug 19, 2026, 07:34 PM UTC
M
MRNA upgraded to Neutral by BAML
Hammerstone MarketTalk reports that BAML upgraded MRNA to a Neutral rating, with no further details on target, catalyst, or timing provided in the feed.
EQUITY | Aug 19, 2026, 05:45 PM UTC
H
Treasury buybacks drag yields lower; gold, miners rally
The Treasury’s decision to at least double long-dated debt buybacks pushed benchmark yields lower, weakened the dollar to its lowest since late May and lifted gold-related assets.
EARNINGS | Aug 19, 2026, 05:10 PM UTC
H
Moderna, Merck cancer vaccine hits key Phase 3 endpoints
Moderna and Merck say their personalized mRNA cancer vaccine intismeran with Keytruda met key endpoints in a Phase 3 melanoma trial, cutting recurrence and distant metastasis versus Keytruda alone.
CENTRAL_BANK | Aug 19, 2026, 05:09 PM UTC
H
MRNA short sellers face ~$4.8B paper losses after jump to $159
Moderna (MRNA) short sellers face about $4.8B in paper losses on Wednesday after the stock surges to $159, according to Ortex estimates.
EQUITY | Aug 19, 2026, 02:39 PM UTC
L
Leerink says cancer vaccine win should sustain Merck momentum into fall
Leerink says a cancer vaccine win should sustain Merck momentum into fall, with the note referencing MRNA, BNTX and MRK and supplying no further catalyst details.
EQUITY | Aug 19, 2026, 02:39 PM UTC